OverviewSuggest Edit

Our first test for uveal melanoma, a rare and deadly eye cancer, is used to identify those at high risk for metastasis. With demonstrated improved accuracy over existing staging and prognostic tools, the test has become the standard of care for uveal melanoma and has successfully secured reimbursement. We are using its innovation as a model for our growing lineup of practice-changing tests, including our newer cutaneous (skin) melanoma prognostic assay. We have active development programs for assays in several other underserved cancers.
Castle Biosciences’ tests are performed in a CLIA-certified, CAP-accredited clinical laboratory.

TypePublic
Founded2008
HQFriendswood, TX, US
Websitecastlebiosciences.com

Recent NewsAll News

Latest Updates

Employees (est.) (Jul 2019)91(+2%)
Revenue (FY, 2019)$51.9 M(+128%)
Share Price (Jan 2021)$79.6 (+5%)
Cybersecurity ratingBMore

Key People/Management at Castle Biosciences

Derek Maetzold

Derek Maetzold

Founder, President, and CEO
Bernhard E. Spiess

Bernhard E. Spiess

COO
Frank Stokes

Frank Stokes

CFO
Toby Juvenal

Toby Juvenal

Senior Vice President, Sales
Bob Cook

Bob Cook

Senior Vice President, Research & Development
Michael Maltby

Michael Maltby

Executive Director, Managed Care
Show more

Castle Biosciences Office Locations

Castle Biosciences has offices in Friendswood and Phoenix
Friendswood, TX, US (HQ)
820 S Friendswood Dr #201
Phoenix, AZ, US
3737 N 7th St #160
Show all (2)

Castle Biosciences Financials and Metrics

Castle Biosciences Revenue

Embed Graph
View revenue for all periods
Castle Biosciences's revenue was reported to be $51.87 m in FY, 2019
USD

Revenue (Q2, 2020)

12.7m

Gross profit (Q2, 2020)

10.6m

Gross profit margin (Q2, 2020), %

83.1%

Net income (Q2, 2020)

(1.4m)

EBIT (Q2, 2020)

(645.0k)

Market capitalization (8-Jan-2021)

2.0b

Closing stock price (8-Jan-2021)

79.6

Cash (30-Jun-2020)

179.8m

EV

1.8b
Castle Biosciences's current market capitalization is $2 b.
Annual
USDFY, 2017FY, 2018FY, 2019

Revenue

13.8m22.8m51.9m

Revenue growth, %

66%

Cost of goods sold

4.9m5.3m7.3m

Gross profit

8.8m17.5m44.6m
Quarterly
USDQ1, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

3.7m8.7m10.7m14.8m17.4m12.7m

Cost of goods sold

1.3m1.6m2.0m1.7m2.4m2.1m

Gross profit

2.4m7.1m8.7m13.1m15.0m10.6m

Gross profit Margin, %

66%82%81%88%86%83%
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

1.2m4.5m98.8m

Accounts Receivable

4.7m12.1m14.6m

Prepaid Expenses

515.5k675.6k2.0m

Inventories

304.6k882.2k1.2m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

16.2m17.5m94.5m98.7m179.8m

Accounts Receivable

9.2m9.7m12.4m14.6m12.5m

Prepaid Expenses

741.4k774.9k2.2m2.1m1.7m

Inventories

809.3k550.9k821.7k1.2m1.7m
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

(12.4m)(6.4m)5.3m

Depreciation and Amortization

270.3k287.1k358.0k

Inventories

(115.6k)(577.7k)(355.0k)

Accounts Payable

370.9k197.2k557.0k
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q1, 2020Q2, 2020

Net Income

(3.6m)(2.6m)3.2m(1.4m)570.0k(806.0k)

Depreciation and Amortization

70.4k167.5k258.5k77.4k91.0k193.0k

Inventories

97.0k331.3k60.6k97.0k19.0k(430.0k)

Accounts Payable

(217.2k)(524.0k)(46.9k)(328.8k)56.0k444.0k
USDFY, 2017

Revenue/Employee

215.5k

Debt/Equity

-1.3 x

Debt/Assets

1.9 x

Financial Leverage

-0.7 x
Show all financial metrics

Castle Biosciences Operating Metrics

Q1, 2019

Clinical Samples Processed to Date

40 k
Show all operating metrics

Castle Biosciences Cybersecurity Score

Cybersecurity ratingPremium dataset

B

84/100

SecurityScorecard logo

Castle Biosciences Online and Social Media Presence

Embed Graph

Castle Biosciences News and Updates

VC-backed Castle Biosciences goes public

Friendswood, Texas-based Castle Biosciences Inc, a dermatological cancer company, has raised $64 million for its IPO after pricing its 4 million shares at $16 per share. The stock began trading July 25, 2019 on the NASDAQ under the ticker symbol "CSTL." SVB Leerink and Baird are the lead underwriter…

Castle Biosciences Blogs

Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2019 Performance Results, Delivering 29% DecisionDx-Melanoma Test Report Volume Growth in 2019

The post Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2019 Performance Results, Delivering 29% DecisionDx-Melanoma Test Report Volume Growth in 2019 appeared first on Castle Biosciences, Inc..

Castle Biosciences Announces Level of Evidence Review on DecisionDx-Melanoma Published in Latest Issue of American Journal of Clinical Dermatology

The post Castle Biosciences Announces Level of Evidence Review on DecisionDx-Melanoma Published in Latest Issue of American Journal of Clinical Dermatology appeared first on Castle Biosciences, Inc..

Castle Biosciences Added to NASDAQ Biotechnology Index

FRIENDSWOOD, Texas–(BUSINESS WIRE)–Dec. 18, 2019– Castle Biosciences, Inc. (Nasdaq: CSTL) today announced that the Company was recently added to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to the market open on Monday, December 23, 2019. The NASDAQ Biotechnology Index is designed t…

Castle Biosciences Presents Expanded Data Supporting Use of DecisionDx-Melanoma Test to Inform Sentinel Lymph Node Biopsy Recommendations

Data was presented during the 16th International Congress of the Society for Melanoma Research FRIENDSWOOD, Texas–(BUSINESS WIRE)–Nov. 25, 2019– Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions…

Castle Biosciences to Present at Upcoming Investor Conferences

FRIENDSWOOD, Texas–(BUSINESS WIRE)–Nov. 20, 2019– Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that Derek Maetzold, president and chief executive officer, will present at t…

Castle Biosciences Reports Third Quarter 2019 Results

Q3 2019 DecisionDx-Melanoma test report volume increased 32% compared to Q3 2018 Q3 2019 recognized revenues increased to $14.8 million, up from $3.7 million in Q3 2018 Q3 2019 gross margin increased to 88%, up from 64% in Q3 2018 December 2019 salesforce expansion Presented clinical validation data…
Show more

Castle Biosciences Frequently Asked Questions

  • When was Castle Biosciences founded?

    Castle Biosciences was founded in 2008.

  • Who are Castle Biosciences key executives?

    Castle Biosciences's key executives are Derek Maetzold, Bernhard E. Spiess and Frank Stokes.

  • How many employees does Castle Biosciences have?

    Castle Biosciences has 91 employees.

  • What is Castle Biosciences revenue?

    Latest Castle Biosciences annual revenue is $51.9 m.

  • What is Castle Biosciences revenue per employee?

    Latest Castle Biosciences revenue per employee is $569.9 k.

  • Who are Castle Biosciences competitors?

    Competitors of Castle Biosciences include Qvella, Claritas Genomics and Response Biomedical.

  • Where is Castle Biosciences headquarters?

    Castle Biosciences headquarters is located at 820 S Friendswood Dr #201, Friendswood.

  • Where are Castle Biosciences offices?

    Castle Biosciences has offices in Friendswood and Phoenix.

  • How many offices does Castle Biosciences have?

    Castle Biosciences has 2 offices.